Article thumbnail

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia

By A Samanta, B Perazzona, S Chakraborty, X Sun, H Modi, R Bhatia, W Priebe and R Arlinghaus

Abstract

Despite the success of imatinib mesylate (IM) in the early chronic phase of chronic myeloid leukemia (CML), patients are resistant to IM and other kinase inhibitors in the later stages of CML. Our findings indicate that inhibition of Janus kinase 2 (Jak2) in Bcr–Abl+ cells overcomes IM resistance although the precise mechanism of Jak2 action is unknown. Knocking down Jak2 in Bcr–Abl+ cells reduced levels of the Bcr–Abl protein and also the phosphorylation of Tyr177 of Bcr–Abl, and Jak2 overexpression rescued these knockdown effects. Treatment of Bcr–Abl+ cells with Jak2 inhibitors for 4–6 h but not with IM also reduced Bcr–Abl protein and pTyr177 levels. In vitro kinase experiments performed with recombinant Jak2 showed that Jak2 readily phosphorylated Tyr177 of Bcr–Abl (a Jak2 consensus site, YvnV) whereas c-Abl did not. Importantly, Jak2 inhibition decreased pTyr177 Bcr–Abl in immune complexes but did not reduce levels of Bcr–Abl, suggesting that the reduction of Bcr–Abl by Jak2 inhibition is a separate event from phosphorylation of Tyr177. Jak2 inhibition by chemical inhibitors (TG101209/WP1193) and Jak2 knockdown diminished the activation of Ras, PI-3 kinase pathways and reduced levels of pTyrSTAT5. These findings suggest that Bcr–Abl stability and oncogenic signaling in CML cells are under the control of Jak2

Topics: Original Article
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:3072513
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1997). Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol
  2. and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia
  3. (2003). BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood
  4. (1994). Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
  5. (2008). BCR-ABL-transformed GMP as myeloid leukemic stem cells.
  6. (2007). BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res
  7. (2008). Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program
  8. (2001). Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science
  9. (2010). Destabilization of Bcr-Abl/Jak2 Network by a Jak2/ Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML). Genes Cancer
  10. (1999). Dominant negative mutants implicate STAT 5 in myeloid cell proliferation and neutrophil differentiation. Blood
  11. (1998). Efficient and rapid induction of a chronic myelogenous leukemialike myeloproliferative disease in mice receiving P210 bcr/abltransduced bone marrow. Blood
  12. (2009). Enhanced Jak2 activation correlates with IL-3 receptor b Chain expression leading to phosphorylation of tyrosine 177 of Bcr-Abl. Blood (51th Am Soc Hematol Annu Meet Abst)
  13. (2007). Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans
  14. Imatinib mesylate resistance through BCRABL independence in chronic myelogenous leukemia.
  15. (1996). Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol
  16. (2009). Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene
  17. (2002). Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene
  18. (2006). Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res
  19. (1996). P210 Bcr-Abl interacts with the interleukin-3 bc subunit and constitutively induces its tyrosine phosphorylation. Cancer Res
  20. (2000). Real-time quantitation of bcr-abl transcripts in haematological malignancies.
  21. (2004). Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood
  22. (2004). regulates its activity. Mol Cell Biol
  23. (1998). Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene
  24. (2005). Simultaneous activation of JAK1 and JAK2 confers IL-3 independent growth on Ba/F3 pro-B cells.
  25. (2007). TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia
  26. (1991). The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell
  27. (2009). The chronic myeloid leukemia stem cell. Clin Lymphoma Myeloma
  28. (2009). The CML stem cell: evolution of the progenitor. Cell Cycle
  29. (2001). The NH (2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol Cell Biol
  30. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.
  31. (2008). The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell
  32. This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works
  33. To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)